America and Britain Strike Tariff-Free Accord on Drugs.
The United Kingdom and the United States have agreed to a landmark commercial pact that will maintain no import taxes on British pharmaceutical shipments entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise expenditure on medicines through the National Health Service (NHS). This pledge secures that import taxes on these key exports will be held at nothing for a period of 36 months.
This deal comes after previous threats to dramatically increase import taxes on patented drug imports, with increases discussed as high as double the cost.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and brings much-needed balance to American-British pharmaceutical trade," a release noted.
Economic Significance
Drugs are one of the the United Kingdom's most significant exports to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that timeframe.
"This deal secures work, boosts funding and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several specific changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to prevent overspending will be capped at 15%. Last year, refunds were more than 20%.
Industry Background
This agreement comes amid a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were exacerbated by claims that US consumers were charged several times more for the same drugs than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been paused or scrapped, while major funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its resources over the previous ten-year period.
